![Pei Xu](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 34 $ al 30/09/2026
Pei Xu is the founder of Zhongchao, Inc., founded in 2019, serving as Chief Financial Officer, Secretary & Director.
Current jobs include Independent Director at Estrella Immunopharma, Inc., and Chief Financial Officer at Zhongchao Medical Technology (Shanghai) Corp.
since 2016.
Former job includes Financial Director at Otsuka (China) Investment Co., Ltd. from 2008 to 2013.
Education includes an undergraduate degree from Jiangxi University of Finance & Economics.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 03/04/2026 | 39 ( 0 % ) | 34 $ | 30/09/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ZHONGCHAO INC. | Fundador | 16/04/2019 |
| ESTRELLA IMMUNOPHARMA, INC. | Director/Miembro de la Junta | - |
Zhongchao Medical Technology (Shanghai) Corp. | Director Financiero/CFO | 01/09/2013 |
| Empresas | Cargo | Fin |
|---|---|---|
Otsuka (China) Investment Co., Ltd. | Director Financiero/CFO | 01/08/2013 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
Otsuka (China) Investment Co., Ltd. | |
Jiangxi University of Finance & Economics
 Jiangxi University of Finance & Economics Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Zhongchao, Inc.
 Zhongchao, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as holding company whose subsidiaries provides healthcare information, education and training services to healthcare professionals | Commercial Services |
Zhongchao Medical Technology (Shanghai) Corp. | |
Estrella Immunopharma, Inc.
 Estrella Immunopharma, Inc. BiotechnologyHealth Technology Operates as a preclinical-stage biopharmaceutical company focusing on cancer therapeutics to address treatment of blood cancers and solid tumors | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
